Erik Maquoi

4.2k total citations · 1 hit paper
59 papers, 3.3k citations indexed

About

Erik Maquoi is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Erik Maquoi has authored 59 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Cancer Research, 23 papers in Oncology and 20 papers in Molecular Biology. Recurrent topics in Erik Maquoi's work include Protease and Inhibitor Mechanisms (34 papers), Peptidase Inhibition and Analysis (17 papers) and Blood Coagulation and Thrombosis Mechanisms (15 papers). Erik Maquoi is often cited by papers focused on Protease and Inhibitor Mechanisms (34 papers), Peptidase Inhibition and Analysis (17 papers) and Blood Coagulation and Thrombosis Mechanisms (15 papers). Erik Maquoi collaborates with scholars based in Belgium, France and Germany. Erik Maquoi's co-authors include Agnès Noël, Jean‐Michel Foidart, Carine Munaut, Nor Eddine Sounni, Désiré Collen, H.R. Lijnen, Françis Frankenne, H.R. Lijnen, Gábor Vörös and Marco Jost and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and PLoS ONE.

In The Last Decade

Erik Maquoi

59 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence

2021 183 citations Géraldine Luis, Shin Nishiumi et al. Redox Biology profile →

Peers

Countries citing papers authored by Erik Maquoi

Since Specialization

Citations

This map shows the geographic impact of Erik Maquoi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Maquoi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Maquoi more than expected).

Fields of papers citing papers by Erik Maquoi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Maquoi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Maquoi. The network helps show where Erik Maquoi may publish in the future.

Co-authorship network of co-authors of Erik Maquoi

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Maquoi. A scholar is included among the top collaborators of Erik Maquoi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Maquoi. Erik Maquoi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bioactive Clerodane Diterpenoids from the Leaves of Casearia coriacea Vent 2023 ·Molecules ·Allison Ledoux, (unknown), (unknown), (unknown), Joëlle Quetin‐Leclercq, Alembert Tiabou Tchinda, Jacqueline Smadja, Anne Gauvin‐Bialecki, Erik Maquoi, Michel Frédérich	4
2	Remodelling of the fibre-aggregate structure of collagen gels by cancer-associated fibroblasts: A time-resolved grey-tone image analysis based on stochastic modelling 2023 ·Frontiers in Immunology ·Cédric Gommes, Thomas Louis, (unknown), Agnès Noël, Silvia Blacher, Erik Maquoi	5
3	Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence breakdown → 2021 ·Redox Biology ·Géraldine Luis, (unknown), Shin Nishiumi, Jonathan Cimino, Silvia Blacher, Erik Maquoi, (unknown), A. Collignon, Rémi Longuespée, (unknown), (unknown), Naïma Maloujahmoum, Charles Pottier, Gabriel Mazzucchelli, Edwin De Pauw, Akeila Bellahcène, Masaru Yoshida, Agnès Noël, Nor Eddine Sounni	183
4	Collagen and Discoidin Domain Receptor 1 Partnership: A Multifaceted Role in the Regulation of Breast Carcinoma Cell Phenotype 2021 ·Frontiers in Cell and Developmental Biology ·Charles Saby, Erik Maquoi, Frédéric Saltel, Hamid Morjani	4
5	Structures of the free and inhibitors-bound forms of bromelain and ananain from Ananas comosus stem and in vitro study of their cytotoxicity 2020 ·Scientific Reports ·Mohamed Azarkan, Erik Maquoi, (unknown), R. Herman, (unknown), (unknown), P. Charlier, Frédéric Kerff	18
6	DDR1 and MT1-MMP Expression Levels Are Determinant for Triggering BIK-Mediated Apoptosis by 3D Type I Collagen Matrix in Invasive Basal-Like Breast Carcinoma Cells 2019 ·Frontiers in Pharmacology ·Charles Saby, Guillaume Collin, (unknown), Émilie Buache, Laurence Van Gulick, Frédéric Saltel, Erik Maquoi, Hamid Morjani	31
7	Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy 2018 ·Clinical Cancer Research ·Pierre Foidart, (unknown), (unknown), Silvia Blacher, (unknown), (unknown), Erik Maquoi, Élodie Montaudon, Sophie Château‐Joubert, Joëlle Collignon, Michel Coibion, (unknown), Elisabetta Marangoni, Agnès Noël, Nor Eddine Sounni, Guy Jérusalem	41
8	A Membrane-Type-1 Matrix Metalloproteinase (MT1-MMP) – Discoidin Domain Receptor 1 Axis Regulates Collagen-Induced Apoptosis in Breast Cancer Cells 2015 ·PLoS ONE ·(unknown), (unknown), Benoît Hennuy, Pierre Geurts, Agnès Noël, Jean‐Michel Foidart, Erik Maquoi	36
9	EGFR Activation and Signaling in Cancer Cells Are Enhanced by the Membrane-Bound Metalloprotease MT4-MMP 2014 ·Cancer Research ·Alexandra Paye, (unknown), (unknown), Jonathan Cimino, Silvia Blacher, Carine Munaut, Didier Cataldo, Jean Michel Foidart, Erik Maquoi, Joëlle Collignon, Philippe Delvenne, Guy Jérusalem, Agnès Noël, Nor Eddine Sounni	34
10	New and Paradoxical Roles of Matrix Metalloproteinases in the Tumor Microenvironment 2012 ·Frontiers in Pharmacology ·Agnès Noël, Ana Gutiérrez‐Fernández, Nor Eddine Sounni, Niels Behrendt, Erik Maquoi, Ida Katrine Lund, Santiago Cal, Gunilla Høyer‐Hansen, Carlos López-Otı́n	87
11	Membrane Type 1 Matrix Metalloproteinase Detection in Tumors, Using the Iodinated Endogenous [ ¹²³ I]-Tissue Inhibitor 2 of Metalloproteinases as Imaging Agent 2010 ·Cancer Biotherapy and Radiopharmaceuticals ·(unknown), Ruth Oltenfreiter, Françis Frankenne, (unknown), Erik Maquoi, Agnès Noël, Jean‐Michel Foidart, Christophe Van de Wiele, Filip De Vos	7
12	Matrix metalloproteinases at cancer tumor–host interface 2007 ·Seminars in Cell and Developmental Biology ·Agnès Noël, Marco Jost, Erik Maquoi	189
13	Up-regulation of Vascular Endothelial Growth Factor-A by Active Membrane-type 1 Matrix Metalloproteinase through Activation of Src-Tyrosine Kinases 2004 ·Journal of Biological Chemistry ·Nor Eddine Sounni, Christian Roghi, (unknown), (unknown), Carine Munaut, Erik Maquoi, Beatriz G. Gálvez, Christine Gilles, Françis Frankenne, Gillian Murphy, Jean‐Michel Foidart, Agnès Noël	114
14	Membrane associated proteases and their inhibitors in tumour angiogenesis 2004 ·Journal of Clinical Pathology ·Agnès Noël, Catherine Maillard, Natacha Rocks, Maud Jost, (unknown), Nor Eddine Sounni, Erik Maquoi, Didier Cataldo, Jean-Michel Foidart	88
15	Influence of membrane‐bound tumor necrosis factor (TNF)‐α on obesity and glucose metabolism 2004 ·Journal of Thrombosis and Haemostasis ·Gábor Vörös, Erik Maquoi, D Collen, H.R. Lijnen	20
16	Stimulation of Matrix Metalloproteinase-9 Expression in Human Fibrosarcoma Cells by Synthetic Matrix Metalloproteinase Inhibitors 2002 ·Experimental Cell Research ·Erik Maquoi, Carine Munaut, Alain Colige, Charles Lambert, Françis Frankenne, Agnès Noël, Frank Grams, Hans‐Willi Krell, Jean‐Michel Foidart	23
17	Paradoxical Stimulation of Matrix Metalloproteinase‐9 Expression in HT1080 Cells by a Broad‐Spectrum Hydroxamate‐Based Matrix Metalloproteinase Inhibitor 1999 ·Annals of the New York Academy of Sciences ·Erik Maquoi, Carine Munaut, Alain Colige, Cécile Lambert, Françis Frankenne, Agnès Noël, Frank Grams, H. W. Krell, Jean‐Michel Foidart	4
18	Expression of stromelysin-3 in the human placenta and placental bed 1997 ·Placenta ·Erik Maquoi, Myriam Polette, (unknown), P. Bischof, Agnès Noël, Axelle Pintiaux, (unknown), (unknown), Robert Pijnenborg, Philippe Birembaut, Jacqueline Foidart	31
19	Changes in the distribution pattern of galectin-1 and galectin-3 in human placenta correlates with the differentiation pathways of trophoblasts 1997 ·Placenta ·Erik Maquoi, Frédéric A. van den Brûle, Vincent Castronovo, Jean‐Michel Foidart	96
20	Stromelysin-3 expression promotes tumor take in nude mice. 1996 ·Journal of Clinical Investigation ·Agnès Noël, Olivier Lefèbvre, Erik Maquoi, (unknown), Marie‐Pierre Chenard, Marcus Mareel, Jean Michel Foidart, Paul Basset, M. C. Rio	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact